C
Csaba P. Kovesdy
Researcher at University of Tennessee Health Science Center
Publications - 649
Citations - 41377
Csaba P. Kovesdy is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 92, co-authored 605 publications receiving 31462 citations. Previous affiliations of Csaba P. Kovesdy include University of California, Irvine & Semmelweis University.
Papers
More filters
Journal ArticleDOI
AST‐120 for preventing progression of chronic kidney disease: What can we conclude from the available evidence?
Journal ArticleDOI
Joint associations of obesity and estimated GFR with clinical outcomes: a population-based cohort study
Marcello Tonelli,Natasha Wiebe,Csaba P. Kovesdy,Matthew T. James,Scott Klarenbach,Braden J. Manns,Brenda R. Hemmelgarn +6 more
TL;DR: It is found that risk prediction tools for people with CKD might be improved by adding information on BMI or other proxies for body size in addition to eGFR and albuminuria on the likelihood of adverse outcomes including death and ESRD.
Journal ArticleDOI
Elevated serum thyrotropin levels and endothelial dysfunction in a prospective hemodialysis cohort.
Amy S. You,Matthew J. Budoff,Irfan Zeb,Naser Ahmadi,Alejandra Novoa,Ferdinand Flores,Sajad Hamal,April Kinninger,Christopher Dailing,Tracy Nakata,Csaba P. Kovesdy,Csaba P. Kovesdy,Danh V. Nguyen,Gregory A. Brent,Gregory A. Brent,Kamyar Kalantar-Zadeh,Kamyar Kalantar-Zadeh,Connie M. Rhee +17 more
TL;DR: In this paper, the authors examined the relationship between serum TSH with impaired temperature rebound and area under the temperature curve (TMP-AUC) using multivariable logistic regression and found that higher TSH levels were associated with worse micro-vascular reactivity measured by DTM.
Journal ArticleDOI
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Rajiv Agarwal,Bertram Pitt,Peter Rossing,Stefan D. Anker,Gerasimos Filippatos,Luis M. Ruilope,Csaba P. Kovesdy,Katherine R. Tuttle,Muthiah Vaduganathan,Christoph Wanner,Sameer Bansilal,Martin Gebel,Amer Joseph,Robert Lawatscheck,George L. Bakris +14 more
TL;DR: In this paper , the authors examined whether cardiovascular risk can be modified with finerenone in patients with Type 2 diabetes and chronic kidney disease (CKD) at a population level.